Debt to Equity Ratio Chart

View Debt to Equity Ratio for AKBLF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 0.0608
March 31, 2026 0.0624
December 31, 2025 0.0649
September 30, 2025 0.0752
June 30, 2025 0.1012
March 31, 2025 0.1409
December 31, 2024 0.2209
September 30, 2024 0.1003
June 30, 2024 0.1031
March 31, 2024 0.1104
December 31, 2023 0.172
September 30, 2023 0.1654
June 30, 2023 0.1745
March 31, 2023 0.1552
December 31, 2022 0.1745
September 30, 2022 0.1654
June 30, 2022 0.1704
March 31, 2022 0.171
December 31, 2021 0.204
September 30, 2021 0.2357
June 30, 2021 0.2407
March 31, 2021 0.2841
December 31, 2020 0.2991
September 30, 2020 0.2991
June 30, 2020 0.2994
Date Value
March 31, 2020 0.3004
December 31, 2019 0.3117
September 30, 2019 0.299
June 30, 2019 0.3012
March 31, 2019 0.2909
December 31, 2018 0.2334
September 30, 2018 0.2271
June 30, 2018 0.2269
March 31, 2018 0.2294
December 31, 2017 0.2304
September 30, 2017 0.2765
June 30, 2017 0.2748
March 31, 2017 0.2731
December 31, 2016 0.2696
September 30, 2016 0.2223
June 30, 2016 0.2234
March 31, 2016 0.2317
December 31, 2015 0.2392
September 30, 2015 0.2549
June 30, 2015 0.2636
March 31, 2015 0.1322
December 31, 2014 0.1376
September 30, 2014 0.1382
June 30, 2014 0.1419
March 31, 2014 0.1422

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Novo Nordisk A/S 0.6333
H. Lundbeck A/S 0.3505
AstraZeneca PLC 0.7166
ANI Pharmaceuticals, Inc. 1.022
Corcept Therapeutics, Inc. 0.0133